207 related articles for article (PubMed ID: 26045887)
1. The advantages of PD1 activating chimeric receptor (PD1-ACR) engineered lymphocytes for PDL1(+) cancer therapy.
Tang X; Li Q; Zhu Y; Zheng D; Dai J; Ni W; Wei J; Xue Y; Chen K; Hou W; Zhang C; Feng X; Liang Y
Am J Transl Res; 2015; 7(3):460-73. PubMed ID: 26045887
[TBL] [Abstract][Full Text] [Related]
2. Tumor PD-L1 co-stimulates primary human CD8(+) cytotoxic T cells modified to express a PD1:CD28 chimeric receptor.
Prosser ME; Brown CE; Shami AF; Forman SJ; Jensen MC
Mol Immunol; 2012 Jul; 51(3-4):263-72. PubMed ID: 22503210
[TBL] [Abstract][Full Text] [Related]
3. The Antitumor Activity of CAR-T-PD1 Cells Enhanced by HPV16mE7-Pulsed and SOCS1-Silenced DCs in Cervical Cancer Models.
Zheng J; Huang J; Ma W; Yang W; Hu B
Cancer Manag Res; 2021; 13():6045-6053. PubMed ID: 34377023
[TBL] [Abstract][Full Text] [Related]
4. Human T cells engineered to express a programmed death 1/28 costimulatory retargeting molecule display enhanced antitumor activity.
Ankri C; Shamalov K; Horovitz-Fried M; Mauer S; Cohen CJ
J Immunol; 2013 Oct; 191(8):4121-9. PubMed ID: 24026081
[TBL] [Abstract][Full Text] [Related]
5. Soluble CD80 restores T cell activation and overcomes tumor cell programmed death ligand 1-mediated immune suppression.
Haile ST; Dalal SP; Clements V; Tamada K; Ostrand-Rosenberg S
J Immunol; 2013 Sep; 191(5):2829-36. PubMed ID: 23918985
[TBL] [Abstract][Full Text] [Related]
6. Targeting and cytotoxicity of chimeric antigen receptor T cells grafted with PD1 extramembrane domain.
Zhang A; Wang S; Sun Y; Zhang Y; Zhao L; Yang Y; Zhang Y; Xu L; Lei Y; Du J; Chen H; Duan L; He M; Shi L; Liu L; Wang Q; Hu L; Zhang B
Exp Hematol Oncol; 2023 Sep; 12(1):85. PubMed ID: 37777797
[TBL] [Abstract][Full Text] [Related]
7. Enhancing T cell anti-tumor efficacy with a PD1-TIGIT chimeric immune-checkpoint switch receptor.
Zhao J; Dong J; Deng C; Zhang Q; Sun S; Li H; Bai Y; Deng H
Oncoimmunology; 2023; 12(1):2265703. PubMed ID: 37808405
[TBL] [Abstract][Full Text] [Related]
8. A chimeric switch-receptor PD1-DAP10-41BB augments NK92-cell activation and killing for human lung Cancer H1299 Cell.
Zhi L; Yin M; Su X; Zhang Z; Lu H; Li M; Guo C; Niu Z; Zhang X; Zhu W
Biochem Biophys Res Commun; 2022 Apr; 600():94-100. PubMed ID: 35217362
[TBL] [Abstract][Full Text] [Related]
9. Molecular mechanisms of programmed cell death-1 dependent T cell suppression: relevance for immunotherapy.
Zuazo M; Gato-Cañas M; Llorente N; Ibañez-Vea M; Arasanz H; Kochan G; Escors D
Ann Transl Med; 2017 Oct; 5(19):385. PubMed ID: 29114543
[TBL] [Abstract][Full Text] [Related]
10. Macrocyclic Compounds from Ansamycin Antibiotic Class as Inhibitors of PD1-PDL1 Protein-Protein Interaction.
Patil SP; Yoon SC; Aradhya AG; Hofer J; Fink MA; Enley ES; Fisher JE; Herb MC; Klingos A; Proulx JT; Fedorky MT
Chem Pharm Bull (Tokyo); 2018; 66(8):773-778. PubMed ID: 30068796
[TBL] [Abstract][Full Text] [Related]
11. PD1-CD28 Fusion Protein Enables CD4+ T Cell Help for Adoptive T Cell Therapy in Models of Pancreatic Cancer and Non-hodgkin Lymphoma.
Rataj F; Kraus FBT; Chaloupka M; Grassmann S; Heise C; Cadilha BL; Duewell P; Endres S; Kobold S
Front Immunol; 2018; 9():1955. PubMed ID: 30214445
[No Abstract] [Full Text] [Related]
12. Adoptive transfer of murine T cells expressing a chimeric-PD1-Dap10 receptor as an immunotherapy for lymphoma.
Lynch A; Hawk W; Nylen E; Ober S; Autin P; Barber A
Immunology; 2017 Nov; 152(3):472-483. PubMed ID: 28670716
[TBL] [Abstract][Full Text] [Related]
13. Programmed Cell Death Protein 1-PDL1 Interaction Prevents Heart Damage in Chronic
Fonseca R; Salgado RM; Borges da Silva H; do Nascimento RS; D'Império-Lima MR; Alvarez JM
Front Immunol; 2018; 9():997. PubMed ID: 29867974
[TBL] [Abstract][Full Text] [Related]
14. MUC1-induced immunosuppression in colon cancer can be reversed by blocking the PD1/PDL1 signaling pathway.
Zhang Y; Dong X; Bai L; Shang X; Zeng Y
Oncol Lett; 2020 Dec; 20(6):317. PubMed ID: 33133253
[TBL] [Abstract][Full Text] [Related]
15. Combining MPDL3280A with adoptive cell immunotherapy exerts better antitumor effects against cervical cancer.
Zheng Y; Yang Y; Wu S; Zhu Y; Tang X; Liu X
Bioengineered; 2017 Jul; 8(4):367-373. PubMed ID: 27754760
[TBL] [Abstract][Full Text] [Related]
16. The PDL1-PD1 axis converts human TH1 cells into regulatory T cells.
Amarnath S; Mangus CW; Wang JC; Wei F; He A; Kapoor V; Foley JE; Massey PR; Felizardo TC; Riley JL; Levine BL; June CH; Medin JA; Fowler DH
Sci Transl Med; 2011 Nov; 3(111):111ra120. PubMed ID: 22133721
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of PD1/PDL1 Expression and Their Clinicopathologic Association in EBV-associated Lymphoproliferative Disorders in Nonimmunosuppressed Patients.
Guo L; Bodo J; Durkin L; Hsi ED
Appl Immunohistochem Mol Morphol; 2019 Feb; 27(2):101-106. PubMed ID: 29084057
[TBL] [Abstract][Full Text] [Related]
18. The Third Generation Anti-HER2 Chimeric Antigen Receptor Mouse T Cells Alone or Together With Anti-PD1 Antibody Inhibits the Growth of Mouse Breast Tumor Cells Expressing HER2
Li P; Yang L; Li T; Bin S; Sun B; Huang Y; Yang K; Shan D; Gu H; Li H
Front Oncol; 2020; 10():1143. PubMed ID: 32766150
[TBL] [Abstract][Full Text] [Related]
19. Programmed Death-1 Ligand-1 (PDL1) Expression Is Associated with the Prognosis of Patients with Stage II/III Gastric Cancer.
Tamura T; Ohira M; Tanaka H; Muguruma K; Toyokawa T; Kubo N; Sakurai K; Amano R; Kimura K; Shibutani M; Maeda K; Hirakawa K
Anticancer Res; 2015 Oct; 35(10):5369-76. PubMed ID: 26408698
[TBL] [Abstract][Full Text] [Related]
20. Characterisation of tumour microenvironment and immune checkpoints in primary central nervous system diffuse large B cell lymphomas.
Alame M; Pirel M; Costes-Martineau V; Bauchet L; Fabbro M; Tourneret A; De Oliveira L; Durand L; Roger P; Gonzalez S; Cacheux V; Rigau V; Szablewski V
Virchows Arch; 2020 Jun; 476(6):891-902. PubMed ID: 31811434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
